Omega Therapeutics News

Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)

TipRanksApr 30 06:33 ET

Express News | HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target

BenzingaApr 30 06:20 ET

MXL, COLM and SPSC Are Among After Hour Movers

Seeking AlphaApr 25 17:31 ET

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA

GlobeNewswireApr 23 07:00 ET

CVAC, SBNY and CRMD Are Among After Hour Movers

Seeking AlphaApr 17 17:01 ET

Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Yahoo FinanceApr 17 09:55 ET

Omega Therapeutics CFO Reed To Depart

By Ben Glickman Omega Therapeutics Chief Financial Officer Joshua Reed will depart the company at the end of the next month, the company said Tuesday. Omega said in a regulatory filing that the comp

WSJApr 16 17:05 ET

Express News | Omega Therapeutics Inc - Designated Barbara Chan as Its Principal Financial Officer and Principal Accounting Officer

Moomoo 24/7Apr 16 16:21 ET

Express News | Omega Therapeutics Inc - on April 10, Co and Joshua Reed, Chief Financial Officer, Agreed to Terminate His Employment Effective as of May 31

Moomoo 24/7Apr 16 16:21 ET

Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024

MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanismValidation of novel translational assay

BenzingaApr 9 07:06 ET

Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know

Yahoo FinanceApr 3 12:00 ET

Piper Sandler Reiterates Overweight on Omega Therapeutics, Lowers Price Target to $9

Piper Sandler analyst Edward Tenthoff reiterates Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price target from $10 to $9.

BenzingaApr 3 11:27 ET

Omega Therapeutics (OMGA) Receives a Buy From Piper Sandler

TipRanksApr 3 07:06 ET

Omega Therapeutics Is Maintained at Buy by Chardan Capital

Omega Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesApr 1 08:34 ET

Express News | Chardan Capital Maintains Buy on Omega Therapeutics, Lowers Price Target to $7

Moomoo 24/7Apr 1 08:24 ET

Omega Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 88.68% Chardan Capital $12 → $7 Maintains Buy 01/04/2024 223.45% Wedbush → $12 Reiterates Outpe

BenzingaApr 1 08:22 ET

We Think Omega Therapeutics (NASDAQ:OMGA) Needs To Drive Business Growth Carefully

Yahoo FinanceMar 29 08:22 ET

Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss

Omega Therapeutics (OMGA) said Thursday it has cut its headcount by about 35% following a strategic review, extending its cash runway into Q1 of 2025. The clinical-stage drugmaker also reported a net

MT NewswiresMar 28 10:33 ET

Express News | Omega Therapeutics Q4 2023 GAAP EPS $(0.37) Beats $(0.47) Estimate

Moomoo 24/7Mar 28 09:18 ET

Omega Therapeutics 4Q Loss/Shr 37c >OMGA

Omega Therapeutics 4Q Loss/Shr 37c >OMGA

Dow JonesMar 28 09:16 ET